eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2024
vol. 28
 
Share:
Send email
Share:
Original paper

Treatment outcomes of patients with BRAFV600E-mutated metastatic colorectal cancer: a Polish retrospective cohort study

Jolanta Żok
1
,
Michał Bieńkowski
2
,
Barbara Radecka
3
,
Agata Kuchar
1
,
Szymon Borowiec
1
,
Joanna Streb
4, 5
,
Michał Jurczyk
5, 6
,
Anna Jakieła-Drąg
7
,
Marek Gełej
3
,
Patryk Zając
3
,
Małgorzata Ploch-Glapińska
7
,
Renata Duchnowska
1

  1. Department of Oncology, Military Institute of Medicine, National Research Institute, Warsaw, Poland
  2. Department of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland
  3. Department of Oncology, Institute of Medical Science, University of Opole, Opole, Poland
  4. Department of Oncology, Jagiellonian University Medical College, University Hospital, Kraków, Poland
  5. Department of Oncology, Jagiellonian University Medical College, Kraków, Poland
  6. Department of Pathophysiology, Jagiellonian University Medical College, Kraków, Poland
  7. Department of Oncology, 4th Military Clinical Hospital with Polyclinic, Wrocław, Poland
Contemp Oncol (Pozn) 2024; 28 (4): 297–303
DOI: https://doi.org/10.5114/wo.2024.146953
Online publish date: 2025/01/15
Article file
- Treatment outcomes.pdf  [0.17 MB]
Get citation
 
PlumX metrics:
 
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249.
2. Cancers in Poland 2020. Available at: https://onkologia.org.pl/sites/default/files/publications/2023-01/nowotwory_2020.pdf (Accessed: 06.11.2023).
3. The announcement of the Minister of Health of 22 August 2022 on the list of reimbursed medicines, foodstuffs for special nutritional purposes and medical devices for 1 September 2022. Available at: https://gov.pl/web/zdrowie/obwieszczenie (Accessed: 06.11.2023).
4. The announcement of the Minister of Health of 20 October 2023 on the list of reimbursed medicines, foodstuffs for special nutritional purposes and medical devices for 1 November 2023. Available at: https://gov.pl/web/zdrowie/obwieszczenie (Accessed: 06.11.2023).
5. European Society for Medical Oncology. Metastatic Colorectal Cancer Living Guideline. Available at: https://www.esmo.org/living-guidelines/esmo-metastatic-colorectal-cancer-living-guideline/advanced-and-metastatic-disease-without-potential-conversion/advanced-and-metastatic-disease-without-potential-conversion/first-line (Accessed: 06.11.2023).
6. National Comprehensive Cancer Network. Guidelines. Colon cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf (Accessed: 06.11.2023).
7. Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 10-32.
8. Taieb J, Lapeyre-Prost A, Laurent Puig P, Zaanan A. Exploring the best treatment options for BRAF-mutant metastatic colon cancer. Br J Cancer 2019; 121: 434-442.
9. Corcoran RB, André T, Atreya CE, et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer. Cancer Discov 2018; 8: 428-443.
10. Cohen R, Liu H, Fiskum J, et al. BRAF V600E mutation in first-line metastatic colorectal cancer: an analysis of individual patient data from the ARCAD database. J Natl Cancer Inst 2021; 113: 1386-1395.
11. Angerilli V, Sabella G, Centonze G, et al. BRAF-mutated colorectal adenocarcinomas: pathological heterogeneity and clinical implications. Crit Rev Oncol Hematol 2022; 172: 103647. DOI: 10.1016/ j.critrevonc.2022.103647.
12. Grothey A, Fakih M, Tabernero J. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Ann Oncol 2021; 32: 959-967.
13. Martinelli E, Cremolini C, Mazard T, et al. Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study. ESMO Open 2022; 7: 100603. DOI: 10.1016/j.esmoop.2022.100603.
14. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2021. https://www.R-project.org.
15. Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual (7th ed). New York, NY: Springer; 2010. DOI: 10.1186/s12874-021-01308-8.
16. Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol 2021; 21: 111. DOI: https://doi.org/10.1186/s12874-021-01308-8.
17. Wickham H. ggplot2: Elegant Graphics for Data Analysis. 1st ed. New York, NY: Springer-Verlag; 2016.
18. Kassambara A, Kosinski M, Biecek P. Survminer: Drawing Survival Curves using ‘ggplot2’. R package version 0.4.9. Survminer; 2021, March 9. https://CRAN.R project.org/package=survminer. DOI: 10.1200/JCO.2009.23.3452.
19. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-474.
20. Seligmann JF, Fisher D, Smith CG, et al. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials. Ann Oncol 2017; 28: 562-568.
21. Falcone A, Ricci S, Brunetti I, et al. Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676.
22. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16: 1306-1315.
23. Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371: 1609-1618.
24. Cremolini C, Loupakis F, Masi G, et al. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. Ann Oncol 2016; 27: 843-849.
25. Cremolini C, Antoniotti C, Rossini D, et al.; GONO Foundation Investigators. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open- label, phase 3, randomised, controlled trial. Lancet Oncol 2020; 21: 497-507.
26. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712.
27. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101: 715-221.
28. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-762.
29. Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015; 51: 587-594.
30. Rowland A, Dias MM, Wiese MD, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 2015; 112: 1888-1894.
31. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 2019; 381: 1632-1643.
32. U.S. Food and Drug Administration. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-combination-cetuximab-metastatic-colorectal-cancer-braf-v600e-mutation (Accessed: 06.11.2023).
33. Trullas A, Delgado J, Koenig J, et al. The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy. ESMO Open 2021; 6: 100031. DOI: 10.1016/j.esmoop.2020.100031.
34. Keikes L, Kos M, Verbeek XAAN, et al. Conversion of a colorectal cancer guideline into clinical decision trees with assessment of validity. Int J Qual Health Care 2021; 33: mzab051. DOI: 10.1093/intqhc/mzab051.
35. Keikes L, Koopman M, Stuiver MM, Lemmens VEPP, van Oijen MGH, Punt CJA. Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in the Netherlands: a population-based study. Acta Oncol 2020; 59: 395403. DOI: 10.1080/0284186X.2020.1722320.
36. Diaz LA Jr, Shiu KK, Kim TW, et al.; KEYNOTE-177 Investigators. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol 2022; 23: 659-670.
37. Lenz HJ, Van Cutsem E, Limon ML, et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase ii checkmate 142 study. J Clin Oncol 2022; 40: 161-170.
38. Zarkavelis G, Amylidi AL, Torounidou N, et al. Exploring RAS mutation incidence and temporal heterogeneity in metastatic colorectal cancer patients – a single-institution experience utilising circulating tumour DNA. Contemp Oncol (Pozn) 2024; 28: 45-50.
Copyright: © 2025 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.